Presented by: Bo Zhai, Cell & Developability Science, Janssen Research & Development
Presentation Abstract: As biopharmaceuticals have been at the center stage of the pipeline of almost every pharmaceutical company, high-yield, stably expressing cell lines are of critical importance for economically viable biopharmaceutical production processes. Tracking CLD process have been proven challenging given the number of clones generated, as well as tests performed to identify producer cell lines suitable for industrial, large-scale manufacturing processes. Using LabKey Biologics, we mapped the whole cell line development process with proper lineage tracking. Associate the molecule entity as well as analytical testing information with samples at different CLD stages effectively reduced clone selection timeline.
Speaker Bio: Bo Zhai is a Senior Scientist at the Cell & Developability Sciences (CDS) group of Janssen Research & Development. He provides mass spectrometry characterization to support programs in the large molecule value stream in both discovery and early development. He also leads efforts in building automated workflows for high throughput data analysis. Bo was a Mass Spec Analytic Scientist at St Jude Children’s Research Hospital developing multiple mass spectrometry based analytical assays for the characterization of biopharmaceuticals under GMP setting. Bo holds a PhD in Biochemistry and Molecular Biology from the Institute of Biochemistry and Molecular Biology, Chinese Academy of Sciences and had his postdoctoral training at Harvard Medical School.